Immix Biopharma, Inc(IMMX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IMMX Immix Biopharma, Inc

未开盘 07-23 16:00:00 EDT

8.80

-0.61

-6.48%

盘后9.00

+0.20+2.27%

19:34 EDT

最高9.46	最低8.78	成交量99.58万
今开9.23	昨收9.41	日振幅7.23%
总市值6.26亿	流通市值5.00亿	总股本7,119万
成交额897.12万	换手率1.75%	流通股本5,678万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc","latestPrice":8.8,"timestamp":1784836800000,"preClose":9.41,"halted":0,"volume":995836,"hourTrading":{"tag":"盘后","latestPrice":9,"preClose":8.8,"latestTime":"19:34 EDT","volume":17999,"amount":158712.5438,"timestamp":1784849644556,"change":0.2,"changeRate":0.022727,"amplitude":0.043182},"delay":0,"changeRate":-0.0648246546227417,"floatShares":56781100,"shares":71190000,"eps":-0.888277,"marketStatus":"未开盘","change":-0.61,"latestTime":"07-23 16:00:00 EDT","open":9.23,"high":9.455,"low":8.775,"amount":8971198.727396,"amplitude":0.072264,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.888277,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784880000000},"marketStatusCode":0,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":9.41,"preHourTrading":{"tag":"盘前","latestPrice":9.21,"preClose":9.41,"latestTime":"09:29 EDT","volume":1310,"amount":12277.00822,"timestamp":1784813399999,"change":-0.2,"changeRate":-0.021254,"amplitude":0.037194},"postHourTrading":{"tag":"盘后","latestPrice":9,"preClose":8.8,"latestTime":"19:34 EDT","volume":17999,"amount":158712.5438,"timestamp":1784849644556,"change":0.2,"changeRate":0.022727,"amplitude":0.043182},"volumeRatio":0.462409,"impliedVol":1.157,"impliedVolPercentile":0.4542},"requestUrl":"/m/hq/s/IMMX","defaultTab":"news","newsList":[{"id":"1145639259","title":"Immix Biopharma, Inc. 净收益将用于资助NXC-201开发、营运资金及公司一般用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1145639259","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145639259?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:31","pubTimestamp":1779359499,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. 宣布，其近期融资所获净收益将专项用于推进其候选疗法NXC-201的临床开发，补充营运资金，以及支持公司其他一般性企业用途。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195941801","title":"Immix Biopharma预计2027年3月底前公布患者1年随访数据，视其为推动BLA申报及商业上市的关键","url":"https://stock-news.laohu8.com/highlight/detail?id=1195941801","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195941801?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:07","pubTimestamp":1779358063,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc.（IMMX）宣布，公司预计将在2027年3月底之前，公布其已入组患者的一年期随访数据。该公司认为，这些临床数据的发布将成为推动其生物制品许可申请（BLA）提交以及后续商业化上市进程的重要驱动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194761394","title":"Immix Biopharma, Inc.：Nexicart-2试验中所有四名MRD阴性患者均转为完全缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1194761394","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194761394?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:03","pubTimestamp":1779357831,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. 宣布，在其Nexicart-2临床试验中，所有四名微小残留病（MRD）阴性的患者均已转化为完全缓解（Complete Response）。这一积极数据标志着该候选疗法在特定患者群体中展现出了显著的疗效潜力。试验结果的公布，进一步推动了公司针对血液肿瘤的CAR-T细胞疗法研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163140504","title":"Immix Biopharma公布复发/难治性AL淀粉样变性临床试验Nexicart-2中期更新：完全缓解率达95%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163140504","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163140504?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:00","pubTimestamp":1779357617,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. (IMMX) 近日公布了其针对复发/难治性AL淀粉样变性的临床试验Nexicart-2的中期数据更新。结果显示，在接受评估的患者中，完全缓解率达到了95%。这一积极数据标志着该公司在该适应症的研发上取得了显著进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158867508","title":"默沙东与Infinimmune达成协议 获得抗体候选药物独家开发及商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1158867508","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158867508?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:08","pubTimestamp":1774958923,"startTime":"0","endTime":"0","summary":"根据最新合作协议，默沙东（MRK）将获得Infinimmune公司抗体候选药物的独家开发及商业化权利。该协议标志着双方在创新疗法领域的重要战略合作，为默沙东的研发管线注入新的生物技术资产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861249.SGD","LU2361044865.SGD","LU1116320737.USD","LU1061106388.HKD","LU1989772923.USD","IE00BJT1NW94.SGD","LU0265550359.USD","LU1917777945.USD","LU1941712264.USD","LU2023250843.SGD","IMMX","IE00BJJMRZ35.SGD","IE00B1BXHZ80.USD","LU0965509101.SGD","LU2089984988.USD","LU0130102774.USD","BK4516","LU0965509283.SGD","LU0320765489.SGD","LU1974910355.USD","LU1934455194.USD","LU1162221912.USD","LU1983299246.USD","IE00BSNM7G36.USD","IE00B2B36J28.USD","LU0320765646.SGD","BK4550","LU0234572021.USD","BK4533","IE00BBT3K403.USD","LU0477156953.USD","LU0211331839.USD","LU1929549753.HKD","LU0238689110.USD","LU0980610538.SGD","LU2361045086.USD","SG9999002224.SGD","LU0203347892.USD","LU2125154778.USD","IE0002141913.USD","SG9999013999.USD","LU0861579265.USD","LU0648001328.SGD","SG9999014542.SGD","LU2106854487.HKD","LU2468319806.SGD","LU0130517989.USD","SG9999001176.SGD","LU1430594728.SGD","SG9999014567.USD","LU1035773651.USD","IE000M9KFDE8.USD","IE0009355771.USD","LU0868494708.USD","LU1989771016.USD","LU0058720904.USD","BK4534","LU2023250504.SGD","LU0266013472.USD","SG9999001440.SGD","BK4007","LU0098860793.USD","LU2461242641.AUD","LU1093756325.SGD","LU1934455277.USD","LU0289739699.SGD","LU1699723380.USD","LU1066053197.SGD","LU0942090050.USD","LU0965509010.AUD","SG9999002232.USD","LU1066051225.USD","LU2324357040.USD","LU1989772840.SGD","LU1057294990.SGD","LU1093756168.USD","MRK","IE00B4R5TH58.HKD","LU1571399168.USD","LU0208291251.USD","LU1023059063.AUD","SG9999015358.SGD","LU1585245621.USD","BK4559","LU2112291526.USD","LU1066051811.HKD","BK4588","IE00BFTCPJ56.SGD","LU0006306889.USD","LU1116320901.HKD","LU2360032135.SGD","LU0985320562.USD","LU1037948897.HKD","SG9999015341.SGD","LU2125154935.USD","LU1066051498.USD","LU1934455863.HKD","SG9999014559.SGD","LU0965508806.USD","LU0432979614.USD","LU1069347547.HKD","LU1941712348.USD","SG9999001176.USD","LU0070302665.USD","SG9999014575.USD","LU0868494617.USD","IE00BN8TJ469.HKD","LU0106261372.USD","LU0122379950.USD","IE00BLSP4452.SGD","LU0203345920.USD","SGXZ57979304.SGD","LU0265550946.USD","LU2361044949.HKD","BK4585","LU1037948541.HKD","IE00BLSP4239.USD","LU1291159041.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140197538","title":"Immix Biopharma宣布完成BLA支持性复发/难治性AL淀粉样变性试验Nexicart-2的患者入组及即将到来的里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1140197538","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140197538?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:47","pubTimestamp":1774874837,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. 已宣布其用于支持生物制品许可申请（BLA）的复发/难治性AL淀粉样变性试验Nexicart-2的患者入组工作顺利完成。该试验的完成标志着公司向监管审批迈出了关键一步。与此同时，公司还公布了接下来的一系列重要研发里程碑，预示着其在AL淀粉样变性治疗领域的持续进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174396373","title":"Immix Biopharma公司于2026年3月25日签订ATM发行协议第一号修正案 - 美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1174396373","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174396373?lang=zh_cn&edition=full","pubTime":"2026-03-26 05:26","pubTimestamp":1774473977,"startTime":"0","endTime":"0","summary":"Immix Biopharma公司于2026年3月25日，就其ATM（按市价发行）发行协议签订了第一号修正案。此项信息已在美国证券交易委员会（SEC）的相关文件中披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614098358","title":"Immix Biopharma, Inc.盘中异动 快速上涨5.18%报8.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614098358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614098358?lang=zh_cn&edition=full","pubTime":"2026-02-25 23:03","pubTimestamp":1772031831,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日23时03分，Immix Biopharma, Inc.股票出现波动，股价急速上涨5.18%。截至发稿，该股报8.93美元/股，成交量12.2318万股，换手率0.23%，振幅4.53%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。其候选产品包括治疗自身免疫性疾病的 CAR-T NXC-201 和治疗软组织肉瘤的 IMX-110。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225230352a4c7bd2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225230352a4c7bd2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608457428","title":"Immix Biopharma, Inc.盘中异动 早盘股价大涨5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608457428","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608457428?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:59","pubTimestamp":1770044347,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时59分，Immix Biopharma, Inc.股票出现波动，股价快速拉升5.80%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。其相关个股中，Psyence Biomedical Ltd.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Celularity Inc C/Wts 16/07/2026 涨幅较大，60 Degrees Pharmaceuticals, Inc.、Vivosim Labs, Inc.、Vyome Holdings, Inc.较为活跃，换手率分别为255.44%、22.77%、16.83%，振幅较大的相关个股有60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Psyence Biomedical Ltd.、Bioatla, Inc.，振幅分别为82.69%、58.49%、40.48%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202225907a473cf70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202225907a473cf70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607722485","title":"Immix Biopharma, Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607722485","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607722485?lang=zh_cn&edition=full","pubTime":"2026-01-29 03:25","pubTimestamp":1769628325,"startTime":"0","endTime":"0","summary":"北京时间2026年01月29日03时25分，Immix Biopharma, Inc.股票出现波动，股价快速上涨5.05%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.68%。其相关个股中，Jasper Therapeutics Inc C/Wts 24/09/2026 、Moolec Science Sa C/Wts 30/01/2028、Psyence Biomedical Ltd.涨幅较大，Gri Bio, Inc.、Calcimedica, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为2303.89%、282.51%、147.77%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Gri Bio, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为90.64%、53.19%、52.83%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129032525953ec9d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129032525953ec9d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518783692","title":"Immix Biopharma, Inc.盘中异动 早盘股价大涨8.55%报1.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518783692","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518783692?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:54","pubTimestamp":1741614857,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时54分，Immix Biopharma, Inc.股票出现波动，股价急速拉升8.55%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2864.76%、638.63%、141.33%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021541796403bef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021541796403bef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516573536","title":"Immix Biopharma, Inc.盘中异动 股价大跌6.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516573536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516573536?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:51","pubTimestamp":1741027863,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时51分，Immix Biopharma, Inc.股票出现异动，股价急速跳水6.68%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Radiopharm Theranostics Limited涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4441.89%、200.42%、179.81%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304025103a25d88ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304025103a25d88ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514062019","title":"Immix Biopharma, Inc.盘中异动 早盘股价大跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514062019","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514062019?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:18","pubTimestamp":1740500329,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时18分，Immix Biopharma, Inc.股票出现波动，股价快速下跌5.23%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1316.81%、1113.72%、895.27%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为224.93%、87.83%、66.67%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001849a2539f88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001849a2539f88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513777338","title":"Immix Biopharma, Inc.盘中异动 大幅跳水5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513777338","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513777338?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:29","pubTimestamp":1740410943,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时29分，Immix Biopharma, Inc.股票出现波动，股价急速跳水5.40%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为202.64%、85.33%、27.77%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为137.23%、55.69%、53.34%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232904962ea66a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232904962ea66a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512196853","title":"Immix Biopharma, Inc.盘中异动 大幅下跌5.56%报1.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512196853","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512196853?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:58","pubTimestamp":1739905107,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时58分，Immix Biopharma, Inc.股票出现波动，股价急速跳水5.56%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Aditxt, Inc.、Allogene Therapeutics, Inc.、Solid Biosciences Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为805.12%、207.44%、166.74%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219025827a24ae432&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219025827a24ae432&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511962316","title":"Immix Biopharma, Inc.盘中异动 早盘急速下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511962316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511962316?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:36","pubTimestamp":1739543790,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时36分，Immix Biopharma, Inc.股票出现异动，股价大幅跳水5.03%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。其相关个股中，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Virpax Pharmaceuticals, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为1235.22%、380.55%、364.53%，振幅较大的相关个股有Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 ，振幅分别为49.61%、21.52%、20.20%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223631abcf07b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223631abcf07b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510486320","title":"Immix Biopharma, Inc.盘中异动 早盘股价大涨5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510486320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510486320?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:35","pubTimestamp":1739198108,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时35分，Immix Biopharma, Inc.股票出现波动，股价大幅拉升5.47%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.23%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Ocean Biomedical, Inc.、Nls Pharmaceutics Ltd.涨幅较大，Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为938.87%、619.57%、259.14%，振幅较大的相关个股有Invivyd, Inc.、Ocean Biomedical, Inc.、Nls Pharmaceutics Ltd.，振幅分别为29.90%、26.71%、22.45%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223508abc9a627&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223508abc9a627&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508948529","title":"Immix Biopharma, Inc.盘中异动 下午盘股价大跌7.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508948529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508948529?lang=zh_cn&edition=full","pubTime":"2025-02-01 04:02","pubTimestamp":1738353746,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日04时02分，Immix Biopharma, Inc.股票出现异动，股价急速下跌7.11%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.涨幅较大，Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.、Silexion Therapeutics Corp较为活跃，换手率分别为2794.95%、2050.42%、208.65%，振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Seastar Medical Holding Corporation，振幅分别为121.11%、80.00%、69.36%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201040227961510c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201040227961510c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507543880","title":"Immix Biopharma, Inc.盘中异动 快速拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507543880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507543880?lang=zh_cn&edition=full","pubTime":"2025-01-29 00:25","pubTimestamp":1738081514,"startTime":"0","endTime":"0","summary":"北京时间2025年01月29日00时25分，Immix Biopharma, Inc.股票出现波动，股价快速上涨5.04%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Silexion Therapeutics Corp、Transcode Therapeutics, Inc.涨幅较大，Silexion Therapeutics Corp、Hepion Pharmaceuticals, Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为4312.10%、3312.00%、2209.07%，振幅较大的相关个股有Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Transcode Therapeutics, Inc.，振幅分别为134.04%、122.16%、102.05%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012900251596130135&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012900251596130135&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506585207","title":"Immix Biopharma, Inc.盘中异动 下午盘股价大跌5.83%报1.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506585207","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506585207?lang=zh_cn&edition=full","pubTime":"2025-01-28 02:10","pubTimestamp":1738001441,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日02时10分，Immix Biopharma, Inc.股票出现异动，股价快速下跌5.83%。截至发稿，该股报1.93美元/股，成交量5.5039万股，换手率0.20%，振幅6.72%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.83%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128021041a2319693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128021041a2319693&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":-0.1064},{"period":"1month","weight":0.0011},{"period":"3month","weight":-0.0747},{"period":"6month","weight":0.7491},{"period":"1year","weight":2.3018},{"period":"ytd","weight":0.7992}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0041},{"period":"3month","weight":0.055},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.1885},{"period":"ytd","weight":0.096}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immix Biopharma, Inc.于2014年1月7日成立为特拉华州公司。公司是一家临床阶段的生物制药公司，专注于嵌合抗原受体细胞疗法（“CAR-T”）在轻链（AL）淀粉样变性和自身免疫性疾病中的应用。公司主导细胞治疗候选药物为美国食品药品监督管理局（“FDA”）研究性新药（“IND”）批准的CAR-T NXC-201，目前正在公司进行的1b/2a期NEXICART-1（NCT04720313）临床试验中进行评估。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035123},{"month":2,"riseRate":0.2,"avgChangeRate":-0.05746},{"month":3,"riseRate":0.2,"avgChangeRate":-0.065433},{"month":4,"riseRate":0.4,"avgChangeRate":-0.025442},{"month":5,"riseRate":0.6,"avgChangeRate":0.091547},{"month":6,"riseRate":0.6,"avgChangeRate":0.103039},{"month":7,"riseRate":0.4,"avgChangeRate":-0.004714},{"month":8,"riseRate":0.25,"avgChangeRate":-0.104667},{"month":9,"riseRate":0.25,"avgChangeRate":0.017421},{"month":10,"riseRate":0.75,"avgChangeRate":0.171445},{"month":11,"riseRate":1,"avgChangeRate":0.264693},{"month":12,"riseRate":1,"avgChangeRate":0.380003}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc(IMMX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immix Biopharma, Inc(IMMX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immix Biopharma, Inc,IMMX,Immix Biopharma, Inc股票,Immix Biopharma, Inc股票老虎,Immix Biopharma, Inc股票老虎国际,Immix Biopharma, Inc行情,Immix Biopharma, Inc股票行情,Immix Biopharma, Inc股价,Immix Biopharma, Inc股市,Immix Biopharma, Inc股票价格,Immix Biopharma, Inc股票交易,Immix Biopharma, Inc股票购买,Immix Biopharma, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc(IMMX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immix Biopharma, Inc(IMMX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}